Talk:Bavituximab
This is the talk page for discussing improvements to the Bavituximab article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Bavituximab.
|
The following Wikipedia contributor has declared a personal or professional connection to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view.
|
Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
The contents of the Bavituximab page were merged into Peregrine Pharmaceuticals. For the contribution history and old versions of the merged article please see its history. |
- Redirect now converted back to independent article.
Which type of analog
[edit]Could someone possibly disambiguate the use of analog in the intro. Rod57 (talk) 01:26, 11 August 2009 (UTC)
Any more info on "3G4, 2aG4, 9d2 and Hu3g4"?
[edit]Does any one know who developed these analogs? Is it the same company that developed Bavituximab (Peregrine Pharma)?Johnfravolda (talk) 05:56, 11 August 2009 (UTC)
Sources
[edit]I used the references box at the top of this page to search pubmed for reviews. There were only two:
- PMID 21843081 is too close to failing WP:INDY as its disclosure says: "DE Gerber receives research support from Peregrine Pharmaceuticals. PE Thorpe serves as a paid consultant, holds stock and has a sponsored research agreement with Peregrine Pharmaceuticals." And the middle author is the inventor, which for some reason they don't disclose. This is not the kind of source I will use for an article about a drug in development
- PMID 21867942 is independent. and I used it.
Outside of those there are few independent sources. I used Adis, which is independent, and I used Peregrines 10-K and a press release to describe the origin of the antibody; the 10-K especially is a highly regulated document so is OK. Jytdog (talk) 06:06, 12 February 2016 (UTC)
Later analysis of SUNRISE patients who went on to have immunotherapy
[edit]They seem to have benefited according to [1] - but that was probably based on a press release so could wait for a MEDRS. - Rod57 (talk) 23:20, 3 December 2017 (UTC)